Protein glycation process

Protein glycation is a non-enzymatic chemical reaction whereby reducing sugars such as glucose, fructose, or galactose form covalent bonds with amino groups in proteins, primarily lysine residues[2]. Unlike glycosylation—an enzyme-mediated, site-specific modification—glycation occurs randomly and disrupts protein structure and function, producing advanced glycation end-products (AGEs), which are implicated in pathological states such as diabetes complications, aging, cardiovascular, and neurodegenerative diseases[2][3][5][6][9]. Glycation leads to protein instability, loss of function, and cross-linking, contributing to tissue stiffness and dysfunction over time[5][6]. Measurement of glycated proteins, such as glycated hemoglobin (HbA1c), is widely used as a biomarker for chronic glucose exposure, especially in diabetes[3]. While glycation itself is not a therapeutic target in the sense of a classical receptor or enzyme, inhibition of glycation or removal of AGEs is a strategy under investigation to prevent or mitigate disease progression[2]. Note: This entry is classified as incorrect as a drug target, since "protein glycation process" describes a biochemical reaction, not a molecule, receptor, or protein suitable for direct targeting by drugs. It cannot serve as a canonical molecular entry for structured databases of therapeutic targets.

Other names

GlycationNon-enzymatic glycosylationprotein glycation

Inhibition of glycation (blocking sugar-protein attachment) Scavenging or breaking advanced glycation end-products